Drug Profile
Bstrongximab ADC - CureMeta
Alternative Names: Bstrongximab; Bstrongximab-MMAE; Bstrongximab-monomethyl auristatin E; CM-09Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator CureMeta
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Podocalyxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Testicular cancer
Most Recent Events
- 18 Sep 2023 Preclinical development for Testicular cancer is ongoing the US (CureMeta pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Testicular-cancer in USA (Parenteral)
- 29 May 2020 Pharmacodynamics data from preclinical trial in Testicular cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)